Shelby Livingston
@ShelbyJLiv
Reporting on health tech for @endpts. Formerly Business Insider, Modern Healthcare. Medill, Clemson. Go Tigers! DM for Signal.
Wearables for everyone? I dug into the evidence behind the health tools RFK wants all Americans to use. endpoints.news/the-trump-admi…
Exclusive: FDA's Makary sought rejection of KalVista’s drug in an unusual move by commissioner, sources say My latest — endpoints.news/sources-fda-ch…
👀
RFK Jr. on the Hill today: “My vision is that every American is wearing a wearable within 4 years.” Says $80/month wearable can achieve similar results as Ozempic. Exploring ways to help pay for.
🎙️Today on @endpts Post Hoc Live, we're going to talk with ex-CDC director @DrMandyCohen about the firing of ACIP by RFK, and what it means for public health and vaccines. We start streaming at 3pm ET! See you there (link in next post)
I'm looking forward to breaking down this story with Dr. Cohen at 3:00pm ET. If you're looking for a primer on ACIP, and how its dismantling could affect the price and uptake of vaccines moving forward, tune in. We'll also address the broader message this sends to public health.
🎙️ Today at 3 p.m. ET on Post-Hoc Live: We break down RFK Jr.’s firing of all CDC vaccine advisers with former CDC head Mandy Cohen and reporter Max Bayer. Tune in on YouTube. @DrMandyCohen @maxonwifi endpoints.news/endpoints-live…
Scoop! Calibrate has replaced its CEO and made several other executive changes, the latest leadership reset at the once high-flying weight loss company. endpts.com/weight-loss-st…
🏆~Another~ big congrats to the @endpts team for two more awards! This time two win's at the @SIIA Neal awards, for @AndrewE_Dunn + our health tech team @lydiapflanzer @ShelbyJLiv + @nyeungs!!!
NEW: Empower Pharmacy, which calls itself the US’ “largest and most advanced” compounding pharmacy has used poor-quality ingredients, skirted regulations and pushed out or sued employees who raised concerns, an Endpoints News investigation found. endpts.com/pharmacy-empow…
$13 billion MA startup Devoted Health grew revenue to $3.3 billion in 2024 and shrank its operating losses, according to my analysis of state insurance filings. endpts.com/devoted-health…
HHS plans to cut 10,000 more staffers in major downsizing - endpts.com/hhs-plans-to-c…
Akido Labs, a California health tech startup, is letting AI take the reins in doctor's visits, all the way from intake to diagnosis to treatment plans. Here's how: endpts.com/how-akido-labs…
Join me Wednesday, March 26 for @endpts inaugural science-focused event, Endpoints Catalysts, where I'll be interviewing leaders in CRISPR gene editing, cell atlases + spatial biology, and regenerative medicine. events.endpts.com/catalysts25
Chatted with GoodRx's new CEO Wendy Barnes. She's focused on speeding up its current growth plans, like leaning into brand name drugs. “The rails exist, but we’ve just got to throw more trains on it. We’ve got to really expand the same strategy.” endpts.com/goodrx-ceo-wen…
The @endpts Health Tech newsletter is a @SABEW winner! Congrats to @lydiapflanzer, @ShelbyJLiv + @nyeungs for building an amazing, smart product that keep the industry informed!
Seeing a ton of reports saying Hims will stop compounding semaglutide (Ozempic/Wegovy). That's incorrect. Hims will no longer offer exact copies, but they will offer semaglutide in dosages that aren't commercially available. Already, that's mostly what they do for GLP-1 users.
No semaglutide shortage, no problem. Hims said Monday that its weight loss biz is projected to drive at least $725 million in revenue this year — almost a third of the revenue Hims expects to pull in across the entire company. endpts.com/hims-eyes-grow…
Since the murder of UnitedHealth's top insurance exec and outpouring of public frustration with delayed and denied care, a major question has circled the giant: Will it change how it does business? So far there’s little sign big reforms are in the works. endpts.com/unitedhealth-g…
We've noticed a huge number of people in the science and medical community joining @bluesky . Endpoints and many of our journalists are already there (we're still on here and LinkedIn). You can find us through our starter pack, come say hi! go.bsky.app/NzDRUhL
When you keep your enemies close... Eli Lilly and Ro have formed an unlikely partnership, with Ro now offering cash-pay Zebpound vials through its app. Recall that Ro has offered compounded GLP-1 drugs, which Lilly and Novo have railed against. endpts.com/eli-lilly-has-…